Bladder cancer patients get new hope from virus therapy
NCT ID NCT07505615
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment called VG161, a virus designed to attack cancer cells, in 20 people with a type of bladder cancer that didn't respond to standard therapy. The virus was given directly into the bladder through a tube. The goal was to see if it is safe and if it can help prevent the cancer from coming back. The trial has been completed, and the results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VG161 (a modified virus that targets and kills cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with bladder cancer that hasn't responded to standard therapy.
What could go wrong
This is an early-phase trial with only 20 patients, so results may not apply widely. The virus may cause side effects or fail to control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center, ShangHai,
Shanghai, Shanghai Municipality, 200032, China